Eisai

HALAVEN

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Eisai

Halaven HCPCS:

J9179

HCPCS Code Descriptor:

Injection, eribulin mesylate, 0.1 mg

Category:

J Code

Halaven NDCs:

62856-0389-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Halaven CPT Codes:

-96409 - Chemotherapy administration, Intravenous, push technique, single or initial substance/drug

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Halaven:

HALAVEN is an Oncology drug manufactured by Eisai and administered via the Intravenous route of administration. The J Code: J9179 is aligned to the drug HALAVEN.

Halaven is a type of cancer medicine belonging to a class of drugs called Mitotic inhibitors. It is thought to work by interfering with the growth and spread of cancer cells throughout the body. Halaven is used to treat breast cancer that is metastatic, which means it has spread to other parts of the body. Halaven may also be used to treat liposarcoma, a type of cancer that develops in fatty tissue throughout the body.

ACCESS PRICING AND MORE BY REGISTERING

J9179 Added Date:

January 1, 2012

J9179 Effective Date:

January 1, 2012

J9179 Termination Date:

HCPCS Active

Halaven billing and coding information can be found through Eisai at the link below:
Halaven patient assistance information can be found through Eisai Patient Support at the URL: http://www.eisaireimbursement.com/
HALAVEN prescribing information can be found at the link below:
Information regarding HALAVEN’s side effects can be found at MedlinePlus